In conclusion, this study indicates that the DPP-4 inhibitor anagliptin reduces fasting levels of Apo B-48, suggesting that the improvements in lipid metabolism induced by anagliptin may be due to the inhibition of intestinal lipid transport, and anagliptin has potential benefits for patients with diabetes and dyslipidemia. The gene discussed is DPP4; the disease is metabolic syndrome.